10x Genomics (NASDAQ:TXG - Get Free Report) CEO Serge Saxonov sold 10,486 shares of the stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $63.69, for a total value of $667,853.34. Following the completion of the transaction, the chief executive officer owned 1,075,349 shares of the company's stock, valued at $68,488,977.81. The trade was a 0.97% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Serge Saxonov also recently made the following trade(s):
- On Monday, August 24th, Serge Saxonov sold 18,545 shares of 10x Genomics stock. The stock was sold at an average price of $63.02, for a total value of $1,168,705.90.
- On Monday, June 22nd, Serge Saxonov sold 30,000 shares of 10x Genomics stock. The shares were sold at an average price of $34.44, for a total value of $1,033,200.00.
10x Genomics Stock Down 5.1%
Shares of 10x Genomics stock opened at $61.54 on Friday. 10x Genomics has a 52 week low of $11.16 and a 52 week high of $66.94. The business's fifty day simple moving average is $48.16 and its 200-day simple moving average is $31.83. The firm has a market cap of $8.02 billion, a PE ratio of -104.30 and a beta of 2.03.
10x Genomics (NASDAQ:TXG - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.14) earnings per share for the quarter, topping analysts' consensus estimates of ($0.24) by $0.10. The business had revenue of $151.04 million during the quarter, compared to analysts' expectations of $146.67 million. 10x Genomics had a negative return on equity of 9.33% and a negative net margin of 12.18%.The company's revenue was down 12.7% compared to the same quarter last year. During the same period in the prior year, the business posted $0.28 EPS. As a group, equities analysts expect that 10x Genomics will post -0.75 earnings per share for the current year.
Wall Street Analysts Forecast Growth
A number of brokerages have weighed in on TXG. Canaccord Genuity Group lifted their price target on shares of 10x Genomics from $50.00 to $60.00 and gave the company a "buy" rating in a research report on Monday, August 10th. Barclays upped their price objective on shares of 10x Genomics from $30.00 to $40.00 and gave the stock an "overweight" rating in a report on Wednesday, June 24th. Stifel Nicolaus set a $50.00 price objective on shares of 10x Genomics in a research report on Friday, August 7th. TD Cowen reiterated a "hold" rating on shares of 10x Genomics in a report on Wednesday, July 15th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of 10x Genomics in a research report on Wednesday, June 24th. Five analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $38.31.
Check Out Our Latest Research Report on 10x Genomics
Hedge Funds Weigh In On 10x Genomics
Hedge funds and other institutional investors have recently bought and sold shares of the company. Elevation Wealth Partners LLC grew its position in 10x Genomics by 332.3% in the 2nd quarter. Elevation Wealth Partners LLC now owns 1,487 shares of the company's stock valued at $57,000 after acquiring an additional 1,143 shares in the last quarter. Geneos Wealth Management Inc. acquired a new stake in shares of 10x Genomics during the fourth quarter worth about $38,000. Larson Financial Group LLC lifted its position in shares of 10x Genomics by 164.4% during the fourth quarter. Larson Financial Group LLC now owns 2,364 shares of the company's stock worth $39,000 after purchasing an additional 1,470 shares in the last quarter. Fifth Third Bancorp purchased a new position in shares of 10x Genomics in the first quarter valued at approximately $50,000. Finally, Nykredit A S purchased a new position in shares of 10x Genomics in the second quarter valued at approximately $126,000. 84.68% of the stock is currently owned by hedge funds and other institutional investors.
10x Genomics Company Profile
(
Get Free Report)
10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.
Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
